73,500 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 73,500 shares of the company's stock, valued at approximately $1,959,000. Hussman Strategic Advisors Inc. owned about 0.26% of Castle Biosciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Algert Global LLC boosted its stake in Castle Biosciences by 0.4% during the third quarter. Algert Global LLC now owns 134,321 shares of the company's stock valued at $3,831,000 after buying an additional 599 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Castle Biosciences by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after purchasing an additional 604 shares during the period. Assetmark Inc. raised its position in Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company's stock valued at $149,000 after purchasing an additional 748 shares during the period. Y Intercept Hong Kong Ltd raised its position in Castle Biosciences by 3.6% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company's stock valued at $690,000 after purchasing an additional 845 shares during the period. Finally, Truist Financial Corp raised its position in Castle Biosciences by 4.6% during the fourth quarter. Truist Financial Corp now owns 21,303 shares of the company's stock valued at $568,000 after purchasing an additional 928 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $31.35, for a total transaction of $61,822.20. Following the sale, the insider now owns 85,748 shares of the company's stock, valued at approximately $2,688,199.80. This trade represents a 2.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.14, for a total value of $229,244.38. Following the sale, the director now directly owns 1,425 shares in the company, valued at $41,524.50. This trade represents a 84.66 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,771 shares of company stock valued at $886,112. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Stock Down 1.5 %

NASDAQ CSTL traded down $0.40 during midday trading on Friday, hitting $25.75. 294,905 shares of the company traded hands, compared to its average volume of 344,013. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The company has a market cap of $721.26 million, a PE ratio of 128.76 and a beta of 0.91. The company's 50-day simple moving average is $27.53 and its 200-day simple moving average is $29.23. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CSTL shares. KeyCorp upped their price objective on Castle Biosciences from $28.00 to $36.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. Stephens reiterated an "overweight" rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Lake Street Capital increased their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Finally, Robert W. Baird increased their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.